These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23939185)

  • 1. Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease.
    Clark IA; Vissel B
    Biochem Pharmacol; 2013 Oct; 86(7):862-71. PubMed ID: 23939185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G; Schlüter OM; Südhof TC
    Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
    Goedert M
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein, Parkinson's disease, and Alzheimer's disease.
    Kim S; Seo JH; Suh YH
    Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S9-13. PubMed ID: 15109581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linker histone H1 binds to disease associated amyloid-like fibrils.
    Duce JA; Smith DP; Blake RE; Crouch PJ; Li QX; Masters CL; Trounce IA
    J Mol Biol; 2006 Aug; 361(3):493-505. PubMed ID: 16854430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E; Crews L; Masliah E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration.
    Spielman LJ; Little JP; Klegeris A
    J Neuroimmunol; 2014 Aug; 273(1-2):8-21. PubMed ID: 24969117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau protein: relevance to Parkinson's disease.
    Lei P; Ayton S; Finkelstein DI; Adlard PA; Masters CL; Bush AI
    Int J Biochem Cell Biol; 2010 Nov; 42(11):1775-8. PubMed ID: 20678581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective.
    Li J; Liu D; Sun L; Lu Y; Zhang Z
    J Neurol Sci; 2012 Jun; 317(1-2):1-5. PubMed ID: 22410257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales.
    Clark I; Atwood C; Bowen R; Paz-Filho G; Vissel B
    Pharmacol Rev; 2012 Oct; 64(4):1004-26. PubMed ID: 22966039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis.
    Azizi G; Mirshafiey A
    Immunopharmacol Immunotoxicol; 2012 Dec; 34(6):881-95. PubMed ID: 22970774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Conformationally altered proteins cause neurodegenerative diseases].
    Ingelsson M; Nilsson L; Basun H; Aquilonius SM; Lannfelt L
    Lakartidningen; 2005 Nov 21-27; 102(47):3542-3, 3545-6, 3549 passim. PubMed ID: 16408392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease.
    Langston JW; Sastry S; Chan P; Forno LS; Bolin LM; Di Monte DA
    Exp Neurol; 1998 Dec; 154(2):684-90. PubMed ID: 9878203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease.
    Schmidt AM; Sahagan B; Nelson RB; Selmer J; Rothlein R; Bell JM
    Curr Opin Investig Drugs; 2009 Jul; 10(7):672-80. PubMed ID: 19579173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondria and neurodegeneration.
    Petrozzi L; Ricci G; Giglioli NJ; Siciliano G; Mancuso M
    Biosci Rep; 2007 Jun; 27(1-3):87-104. PubMed ID: 17486441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidation and nitration of α-synuclein and their implications in neurodegenerative diseases.
    Chavarría C; Souza JM
    Arch Biochem Biophys; 2013 May; 533(1-2):25-32. PubMed ID: 23454347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetics in neurodegeneration: a new layer of complexity.
    Marques SC; Oliveira CR; Pereira CM; Outeiro TF
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):348-55. PubMed ID: 20736041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent systemic infections with Streptococcus pneumoniae do not aggravate the course of experimental neurodegenerative diseases.
    Ebert S; Goos M; Rollwagen L; Baake D; Zech WD; Esselmann H; Wiltfang J; Mollenhauer B; Schliebs R; Gerber J; Nau R
    J Neurosci Res; 2010 Apr; 88(5):1124-36. PubMed ID: 19859962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.
    Neff F; Wei X; Nölker C; Bacher M; Du Y; Dodel R
    Autoimmun Rev; 2008 Jun; 7(6):501-7. PubMed ID: 18558370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.